Two sets of CNS efficacy data from integrated analyses of the pivotal phase II STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented, including a poster presentation evaluating the efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC, who have CNS metastases at baseline; and an oral presentation evaluating the intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours with baseline CNS metastasis. In addition, an updated integrated analysis of the phase II STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials, investigating the efficacy and safety of entrectinib in locally advanced/metastatic ROS1-positive NSCLC, which evaluated a larger dataset with longer follow-up (15.8 months) will be presented.
